iclight, Nobody is hyping NYAS and ASCO as catalysts for the stock. These events are being promoted because they are important world-renowned conferences in the medical community.
The value of this cell-based immunotherapy platform technology will be determined by the integrity of the science, and the regulatory process will be the catalyst.
Medical conferences are significant. Merck and Pfizer are sponsors of the NYAS event coming up in a few weeks and the conference will be an excellent source to learn about the latest breakthroughs in the field of cancer immunotherapy. PD1 combo will probably be one of the most notable highlights this year!
Market Data 
Markets 
AI
